Phase 1 vs Phase 2 — Neurology Deal Valuation Comparison
Market Analysis
The Phase 1 to Phase 2 transition in neurology represents a significant value inflection point. Phase 2 deals carry a median total deal value of $3.0B compared to $1.6B at Phase 1, a 87% premium reflecting clinical de-risking. Upfront payments increase from $112M to $343M.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the deal value premium from Phase 1 to Phase 2 in neurology?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating